Dorb isn't getting any value for its biodefense business Maybe it shouldn't get any value but some company's entire market caps are based on it, like cbli dor's Orbec is a pipeline unto itself. acute GVHD prophylaxis gvhd treatment for radiation therapy for cancer IBS